PHE's Seabury and Sood Promote Development of Antimicrobial Drugs in Health Affairs Blog Commentary
As global health leaders gather in Berlin from May 19-20 for the first-ever G20 Health Ministers’ meeting, one of the main topics of discussion is expected to be how to best fight the threat of antimicrobial resistance (AMR). In a new Health Affairs blog post, PHE scientific advisors Seth Seabury and Neeraj Sood propose a new model for the development of antimicrobial drugs. Market entry awards, exclusivity extensions and priority review vouchers are all critical tools that the authors examine, weighing their strengths and weaknesses.
To read the complete blog, please click here.
By: Jason Shafrin, PhD Sr. Director, Policy and Economics and Jacki Chou, MPL Senior Director, Policy and Economics The recent announcement that CVS Caremark will use value-based metrics to inform formulary design at first appears a step in the right direction. However, using value measurements from a single nongovernmental organization—the Institute for Clinical and Economic Review (ICER)—based on a limited picture of treatment value may be problematic. Using this single assessment of value in an effort solely to exclude drugs from a major insurance formulary is even more worrisome and fails to recognize the heterogeneity in patient clinical needs and preferences.